Zomigon (Zomig) is an oral, selective 5-hydroxytryptamine (5-HT 1B/1D ) receptor agonist for acute treatment of migraine attacks with or without aura in adults. This medicine contains zolmitriptan, which is one of the more recent medications designed specifically for migraine. This family of medications, to which zolmitriptan belongs, are often referred to as ‘triptans’.
Several changes in the brain are involved in the development of migraine attacks. Migraines are believed to result from nerve activity and swelling of the blood vessels in the brain. Zomigon acts at several of these sites that are thought to be involved in producing migraine symptoms, such as the blood vessels in the brain and the nerves involved in the signalling of the headache.
Zolmitriptan works by stimulating receptors called serotonin (or 5HT) receptors that are found in the brain. A natural substance called serotonin normally acts on these receptors, causing blood vessels in the brain to narrow. Zolmitriptan mimics this action of serotonin by directly stimulating the serotonin receptors in the brain. This narrows the blood vessels and so relieves the pain of migraine headaches.
Zomigon is specifically developed for the treatment of migraine pain. It is known to relieve migraine headaches by narrowing the blood vessels in the head. Zomigon also reduces substances in the body that can trigger headache pain, nausea, sensitivity to light and sound, and other migraine symptoms. Pain relief should come in one hour with a single 2.5 mg tablet.
Directions for use:
The dose of zolmitriptan should be taken as early as possible after the migraine headache has started, though it is also effective if taken at a later stage during the migraine attack.
Single doses of 1, 2.5 and 5 mg of zolmitriptan were effective for the acute treatment of migraines in adults. In the only direct comparison of 2.5 and 5 mg, there was little added benefit from the larger dose but side effects are generally increased at 5 mg. Patients should, therefore, be started on 2.5 mg or lower. A dose lower than 2.5 mg can be achieved by manually breaking a 2.5 mg tablet in half. If the headache returns, the dose may be repeated after 2 hours, not to exceed 10 mg within a 24 hour period.
Patients with moderate to severe hepatic impairment have decreased clearance of zolmitriptan and significant elevation in blood pressure was observed in some patients. Use of a low dose with blood pressure monitoring is recommended.
Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Seek emergency medical attention if you think you have used too much of this medicine.
Zomigon belongs to a group of head ache medications.
Zomigon Safety Info
Zomigon is contraindicated in patients who are hypersensitive to zolmitriptan or any of its inactive ingredients.
Zolmitriptan may increase blood pressure, it should not be given to patients with uncontrolled hypertension or ischemic heart disease, it should not be administered to patients with hemiplegic or basilar migraine, or any cardiovascular disease, it should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication, and should not be used within two weeks of discontinuation of MAO A inhibitor therapy.
Zolmitriptan can cause serious side effects on the heart, including heart attack or stroke. Although these side effects are rare, do not use this medication if you have a history of heart disease, heart attack or stroke, angina or blood circulation problems. Before using Zomigon, tell your doctor if you have coronary artery disease, or risk factors for coronary artery disease, high blood pressure, liver or kidney disease and if you are using any other drugs. If you have any of these conditions, you may need a dose adjustment or special tests to safely take Zomigon.
There are no adequate and well controlled studies in pregnant women; therefore, zolmitriptan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether zolmitriptan is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when zolmitriptan is administered to a nursing woman.
Zolmitriptan can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert.
Zomigon is generally well tolerated. Most adverse reactions were mild and transient and did not lead to long-lasting effects. Your doctor may want to give your first dose of this medicine in a hospital or clinic setting to see if you have any serious side effects.
Tell your doctor about any unusual or bothersome side effect. Stop using Zomigon and call your doctor at once if you have any serious side effects or signs of an allergic reaction (such as chest pain, pain spreading especially on one side of the body, sudden headache, hallucinations, difficulty breathing, sudden and severe stomach pain and bloody diarrhea, numbness or tingling and a pale or blue-colored appearance in your fingers or toes).
Zomigon Side Effects
- weakness, dizziness
- dry mouth, upset stomach
- pain in the neck, throat, or jaw